New methods for the staging of colorectal cancer using noninvasive techniques

Seminars in Surgical Oncology

Volumn 12, Issue 4, 1996, Pages 253-263

  Blend, Michael J ^a   Abdel Nabi, Hani ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

colorectal patients; PET imaging; radioimmunoscintigraphy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY I 123; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY IN 111; MONOCLONAL ANTIBODY TC 99M; ONCOSCINT; UNCLASSIFIED DRUG;

BENIGN TUMOR; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, NEOPLASM; CARCINOMA; COLONIC NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; RECTAL NEOPLASMS; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030017141     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199607/08)12:4<253::AID-SSU4>3.0.CO;2-4     Document Type: Review

References (57)

1. Miller AB: Cancer Screening, section 4. In DeVita VT, Hellman S. Rosenberg SA (eds) Principles and Practice of Oncology. 3rd Ed. New York: JB Lippincott. 1989, p478-485
2. White RI Jr Interventional radiology Reflections and expectations. The 1985 Eugene P Pendererass New Horizons Lecture. Radiology 162:593-600, 1987
3. Claman HN: The Biology of the Immune Response. JAMA 268:2790-2796, 1992.
4. Pressman D. Komgold L: The in vivo localization of antiWagner osteogenic sarcoma with labeled antibodies. Cancer 6:7619-7623, 1953.
5. Sakahara H, Onodera H, Kobayashi H, et al.: Reduced bone marrow uptake of indium-111 labeled monoclonal antibody after radiotherapy. Eur J Nucl Med 21:1252-1253, 1994.
6. Blend MJ, Levi H, Hyun H: Effect of radiation therapy on In-III-B72.3 MoAb-GYK-DTPA Uptake in Bone Marrow and Tumor Tissue. Radiology 197(P):385, 1995.
7. Britton KE, Buraggi GL, Bares R, et al.: A brief guide to the practice of radioimmunoscintigraphy in cancer. Intl J Biol Markers 4:106-118, 1989.
8. Bares R, Fass J, Weiller G, et al.: Planar vs SPECT radioimmunoscintigraphy, clinical experience with Tc-99m. In-111 and 1-131 labelled monoclonal antibodies against CEA and/or Ca 19.9. Nuklearmedizin 4:24-25, 1987.
9. Abdel-Nabi HH, Schwanz AN, Goldfogel G, et al.: Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. Radiology 166:747-752, 1988.
10. Berche C, Mach JP, Lumbroso JD, et al.: Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. BMJ 285:1447-1451, 1982.
11. Kramer EL, Sanger JJ, Walsh C, et al.: Contribution of SPECT to imaging gastrointestinal adenocarcinoma with In-111-labeled anti-CEA monoclonal antibody. AJR 151:697-703, 1988.
12. Loats H: CT and SPECT Image Registration and Fusion for Spatial Localization of Metastatic Processes Using Radiolabeled Monoclonals. J Nucl Med 34:562-566, 1993.
13. Goldenberg A, Masui H, Divgi C, et al.: Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst, 81:1616-1625, 1989.
14. Lind P, Lechner P, Eber O, et al.: A prospective study of CEA immunoscintigraphy with a Tc-99m-labeled antibody fragment (IMMU-4 Fab') in colorectal cancer patients. J Nucl Med 32:1051-1055, 1991.
15. Swayne LC, Goldenberg DM, Diehl WL, et al.: SPECT Anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases. Clin Nucl Med 16:849-852, 1991.
16. Beatty JD, Duda RB, Williams LE et al.: Preoperative imaging of colorectal carcinoma with In-111-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 46:6494-6502, 1990.
17. Collier BD, Foley WD: Current imaging strategies for colorectal cancer. J Nucl Med 34:537-540, 1993.
18. Goldenberg DM, Goldenberg H, Sharkey RM, et al.: Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragment labeled with 1-123 or Tc-99m. Cancer Res 50:909-921, 1990.
19. Winzelberg GG, Grossman SJ, Rizk S, et al.: Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer Cancer 69:1656-1663, 1992.
20. Collier BD, Abdel Nabi H, Doerr RJ, et al.: Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 185:179-186, 1992.
21. Vijayakumar V, Blend MJ, Johnson DK, et al.: Improved detection of hepatic lesions using a modified In-111 labeling technique in patients with recurrent colon cancer. Nucl Med Commun 14:658-666, 1993.
22. Huffman T, Kenimer J, Stein KE: Regulatory issues surrounding therapeutic use of monoclonal antibodies: points to consider in the manufacture of injectable products intended for human use. In Reisfeld RA. Sell S (eds). Monoclonal Antibodies and Cancer Therapy UCLA Symposia on Molecular and Cellular Biology. New York. Alan R. Liss, 1985, p431-440.
23. Blend MJ, Greager JA, Atcher RA, et al.: Improved radioimmunodetection of human sarcoma transplants in nude mice using a new method for the chelation of indium-111. J Nucl Med 29:-1810-1816, 1988.
24. Baum RP, Lorenz M, Hottenrott C, et al.: Immunoscintigraphy of known and occult metastatic colorectal carcinoma with Tc-99m anti-CEA monoclonal antibody. J Nucl Med 29:834-837, 1988.
25. Patt YZ, Lamki LM, Haynie TP, et al.: Improved tumor localization with increasing dose of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 6:1220-1230, 1988.
26. Reynolds JC, Del Vecchio S, Sakahara H, et al.: Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol Int J Radiat Appl Instrum B 16:121-125, 1989.
27. LoBuglio AF, Wheeler RH, Trang J, et al.: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220-4224, 1989.
28. Pinsky CM, Goldenberg DM, Wlodkowski TJ, et al.: Detection of occult metastases of colorectal cancer by the use of anti-CEA Fab fragments labeled with Tc-99m. J Nucl Med 32:1053, 1991.
29. Som P, Atkins HL, Bandoypadnyoy D, et al.: A fluorinated glucose analog, 2-fluro-2-deoxy-D glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med, 21:670-675, 1980.
30. Adler LP, Blair HF, MaKley JT, et al.: Non-invasive grading of musculoskeletal tumors usine PET. J Nucl Med 32:1508-1512, 1991.
31. Strauss LG, Clorius JH, Schlag P, et al.: Recurrence of colorectal tumors: PET evaluation. Radiology 170:329-332, 1989.
32. Strauss LG, Conti PS: The application of PET in clinical oncology. J Nucl Med 32:623-648, 1991.
33. Gupta NC, Falk P, Frank AR, et al.: PET-FDG imaging for pre-operative staging of colorectal carcinoma. Radiology 185(P):10, 1992.
34. Nabi H: PET-FDG staging of patients with primary colorectal carcinoma: Does it really help? Presented at the Seventh Annual International PET Conference in San Francisco, CA, October 25-29, 1995.
35. Pounds TR, Valk PE, Haseman MK, et al.: Whole body PET-FDG imaging in diagnosis of recurrent colorectal cancer. J Nucl Med 36(P):57, 1995.
36. Scott AM, Berlangieri SU, Zalcberg J, et al.: Detection of recurrent colorectal carcinoma with F-18 FDG positron emission tomography (PET). J Nucl Med 36(P):107, 1995.
37. Shields AT, Graham NM, Helton S, Shields AF: Utility F-18 FDG Pet in preoperative evaluation of patients with colon carcinoma metastatic to liver. J Nucl Med 36(P): 107, 1995.
38. Abdel-Nabi H, Lamonica D, Spaulting M, et al.: Localization of occult recurrent colorectal cancers with F18 FDG whole body Pet: Comparison with conventional diagnostic modalities. J Nucl Med 36(P): 106, 1995.
39. Rosenblum MG, Lamki LM, Murray JL, et al.: Interferon induced changes in pharmacokinetics and tumor uptake of In-111 labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 80:160-165, 1988.
40. Greiner JW, Hand PH, Noguchi P, et al.: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte a-interferon treatment. Cancer Res 44:3208-3214, 1984.
41. Greiner JW, Guadagni F, Noguchi P, et al.: Recombinant Interferon enhances monoclonal antibody targeting of carcinoma lesions in vivo. Science 235:895-898, 1987.
42. Blumemhal RD, Sharkey RM, Snyder D, et al.: Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1. Cancer Res 48:5403-5406, 1988.
43. Leichner PK, Yang NC, Frankel TL, et al.: Dosimetry and treatment planning for Y-90 labeled antiferritin in hepatoma. Int J Radial Oncol Biol Phys 14:1033-1042, 1988.
44. Schlom J, Hand PH, Greiner JW, et al.: Innovations that influence the pharmacology of monoclonal anlibody guided tumor targeting. Cancer Res 50(suppl):820s-827s. 1990.
45. Steis RG, Carrasquillo JA, McCabe R, et al.: Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476-490, 1990.
46. Larson SM: Clinical Radioimmunodetection. 1978-1988: Overview and Suggestions for Standardization of Clinical Trials. Cancer Res 50 (suppl):892-898s, 1990.
47. Ohuchi E: Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. Int J Cancer 40:726-733, 1987.
48. Abdel-Nabi H, Doerr RJ: Localization of colorectal carcinoma with a combination of In-111 CYT-111 and In-111 CYT-372 monoclonal antibodies. J Nucl Med 35:11P, 1994.
49. Alvarez VL, Radcliff, RD, Coughlin DJ, et al.: Molecular recognition units and radioimaging of human disease. In Haseman MK (ed): Diagnostic Uses of Radiolabeled Monoclonal Antibodies. Washington DC: American College of Nuclear Physicians, 1992, p111-128.
50. Order SE, Sleeper AM, Stillwagon GW, et al.: Radiolabeled antibodies. Results and potential cancer therap. Oncology 3:115-120, 1989.
51. Fawwaz RA, Wang TS, Srivastava S, et al.: Potential of palladium-109 labeled antimelanoma monoclonal antibody for tumor therapy. J Nucl Med 25:796-799, 1984.
52. Blumenthal RD, Sharkey RM, Snyder D, et al.: Reduction by anti-antibody administration of the radiotoxicity associated with I-131 labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J Natl Cancer Inst 81:194-199, 1989.
53. Lamki LM: Radioimmunoscintigraphy of cancer: Problems, pitfalls, and prospect. Nucl Med Annu 113-150, 1990.
54. Nudlemann LI, Cabot R, Benjamin IS, et al.: Hepatic reaction for secondary tumors. Cancer Surv 8:33-47, 1989.
55. Pickren JW, Tsukaday Y, Lane WW: Liver metastases: analysis of autopsy data. In Weiss L. Gilbert HA (eds): Liver Metastases. Boston: 1982, p 2-18.
56. Markowitz A, Saleemi K, Freeman LM: Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma. Clin Nucl Med, 18:685-699, 1993.
57. Goldenberg DM, Larson SM: Radioimmunodetection in cancer identification. J Nucl Med 33:803-814, 1992.